Phase 1, Open Label Study to Assess the Safety and Tolerability of U3-1565 in Subjects with Advanced Solid Malignant Tumors (Daiichi Pharmaceutical Corporation #U13565-A-U101).
Phase of Trial: Phase I
Latest Information Update: 28 Jul 2018
At a glance
- Drugs U3 1565 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Daiichi Sankyo Company
- 28 Jul 2018 Results published in the Investigational New Drugs
- 10 Jun 2017 Biomarkers information updated
- 16 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.